7 active trials 4 recruiting 1 Phase 3 10 disease areas 2 changes in 30 days
| Phase 1 | 6 | |
| Phase 3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT07625644 | BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell… | Small Cell Lung Cancer Extensive Stage | Not Yet Recruiting | 2026-07-16 |
| Phase 1 | ||||
| NCT06714591 | Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | 2026-07-21 |
| NCT06293898 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Endometrial Cancer | Recruiting | 2026-07-20 |
| NCT07080242 | Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung… | Small Cell Lung Cancer Metastatic or Locally Advanced | Recruiting | 2026-07-20 |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer… | Non Small Cell Lung Cancer | Recruiting | 2026-01-29 |
| NCT07021066 | Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects… | Gastric Adenocarcinoma | Active, Not Recruiting | 2026-08-05 |
| NCT06714617 | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors | Breast Cancer Stage III | Active, Not Recruiting | 2025-11-04 |
Lung Cancer (5) · Small Cell Lung Cancer (3) · Breast Cancer (3) · Ovarian Cancer (3) · Non-Small Cell Lung Cancer (NSCLC) (2) · Cervical Cancer (2) · Endometrial Cancer (2) · Esophageal Cancer (2) · Gastric Cancer (2) · Bladder Cancer (2)